<DOC>
	<DOCNO>NCT02292875</DOCNO>
	<brief_summary>Grass pollen allergen recognise major cause allergic disease humans animal . Worldwide , least 40 % allergic patient sensitise grass pollen allergens 50-90 % hayfever seasonal allergy sufferer allergic grass pollen . ToleroMune Grass novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment grass allergy . The purpose optional observational follow-on study evaluate rhinoconjunctivitis symptom exposure Grass EEU among subject complete dose visit study TG002 approximately two year start treatment .</brief_summary>
	<brief_title>ToleroMune Grass Follow Study</brief_title>
	<detailed_description>This follow-up study multi-centre , randomise , double-blind , placebo control , parallel group clinical study ( TG002 ) evaluate efficacy , safety tolerability three dos ToleroMune Grass versus placebo grass allergic subject . Subjects complete TG002 calendar year 2012 undergo single exposure grass allergens EEU .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Previously randomise study TG002 , complete treatment visit PTC calendar year 2012 `` Partly control '' `` uncontrolled '' asthama History anaphylaxis grass allergen FEV1 &lt; 80 % predict Treatment betablockers , alphaadrenoreceptor blocker , tranquilizer psychoactuve drug Symptoms clinically relevant illness Subjects tolerate allergen challenge EEU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Grass Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Environmental Exposure Unit</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>ToleroMune Grass</keyword>
</DOC>